These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29369198)

  • 1. Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis.
    Liu H; Yang C; Lu W; Zeng Y
    Medicine (Baltimore); 2018 Jan; 97(4):e9702. PubMed ID: 29369198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.
    Li J; Gao JZ; Du JL; Wei LX
    World J Gastroenterol; 2014 May; 20(20):6336-44. PubMed ID: 24876756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis.
    Xiao WK; Qi CY; Chen D; Li SQ; Fu SJ; Peng BG; Liang LJ
    BMC Cancer; 2014 Feb; 14():104. PubMed ID: 24548704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.
    Zhang J; Zhang M; Ma H; Song X; He L; Ye X; Li X
    Medicine (Baltimore); 2018 Jun; 97(24):e11130. PubMed ID: 29901640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma.
    Moudi B; Heidari Z; Mahmoudzadeh-Sagheb H
    Virusdisease; 2019 Jun; 30(2):193-200. PubMed ID: 31179356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
    Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
    Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
    Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
    Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
    PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
    Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
    Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
    Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature.
    Yang SL; Fang X; Huang ZZ; Liu XJ; Xiong ZF; Liu P; Yao HY; Li CH
    Dis Markers; 2014; 2014():127831. PubMed ID: 25378766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
    Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
    Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
    Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
    APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
    Haruyama Y; Kataoka H
    World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
    Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
    FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation.
    Wang YL; Zhu ZJ; Teng DH; Yao Z; Gao W; Shen ZY
    World J Gastroenterol; 2012 May; 18(19):2408-14. PubMed ID: 22654434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
    Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
    Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis.
    Xu D; Su C; Sun L; Gao Y; Li Y
    Ann Hepatol; 2019; 18(1):58-67. PubMed ID: 31113610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
    Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
    J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.
    Xu C; Yan Z; Zhou L; Wang Y
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1417-24. PubMed ID: 23743582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.